Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration

Go back to Resources

Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration

Authors:

Volume:

Pagination:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment

Go back to Resources

Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir

Go back to Resources

SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Validation of human telomere length multi-ancestry meta-analysis association signals identifies POP5 and KBTBD6 as human telomere length regulation genes

Go back to Resources

Validation of human telomere length multi-ancestry meta-analysis association signals identifies POP5 and KBTBD6 as human telomere length regulation genes

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal

Go back to Resources

Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease

Go back to Resources

Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

An Overview of Data Management in Human Subjects Research

Go back to Resources

An Overview of Data Management in Human Subjects Research

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Go back to Resources

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Authors:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies

Go back to Resources

Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)

Go back to Resources

Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 236
  • Page 237
  • Page 238
  • Page 239
  • Current page 240
  • Page 241
  • Page 242
  • Page 243
  • Page 244
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification